Barinthus Bio's celiac vaccine faces H2 2026 safety readout for AVALON
The Phase 1 AVALON trial tests whether VTP-1000's multiple-dose safety and antibody data hold up after single-dose results and a pending Clywedog merger reset expectations.
Executive Summary
- Barinthus Biotherapeutics is running a small, safety-focused Phase 1 trial testing whether its celiac disease vaccine candidate is tolerable at multiple doses, building on single-dose data the company has already generated.
- The trial's completion timeline slipped again, pushing the primary completion date out several months, while the design and enrollment target held steady, a pattern consistent with routine trial administration rather than distress.
- No other program in celiac disease shares this vaccine's T-cell tolerance-induction mechanism, placing it in mechanistic isolation within a field otherwise pursuing enzyme, peptide, and antibody approaches.
- The upcoming readout will show safety and antibody changes after multiple doses and a gluten challenge, an early tolerability signal rather than a clinical efficacy result.
The trial
AVALON (NCT06310291) is an Early Phase 1 study of VTP-1000 in 45 adults with celiac disease, randomized to active drug or placebo. The trial's nine primary endpoints are safety measures: ECG changes, laboratory abnormalities, vital signs, physical exam findings, treatment-emergent adverse events, and changes in anti-tissue transglutaminase IgA antibodies, a marker of the disease's autoimmune activity. The multiple ascending dose portion adds a gluten challenge following three doses of study drug, a design meant to test whether the vaccine changes the immune response to gluten exposure. NCT06310291+1VTP-1000 in Adults With Celiac DiseaseNCT06310291Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate DevelopmentsApr 30, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
The disclosure
Barinthus said in an April 30, 2026 shareholder update that it already has single ascending dose data in hand and that multiple ascending dose data are expected in the second half of 2026. Chief Executive Officer Bill Enright said the company sees "a clear opportunity for VTP-1000 to deliver near-term clinical milestones" based on that single-dose data. The trial has not posted results on ClinicalTrials.gov as of the most recent check. BarinthusBarinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate DevelopmentsApr 30, 2026
Timing shift
The trial's primary completion date moved from June 1, 2026 to November 1, 2026, a change registered on June 18, 2026. That is the trial's second primary completion date change since its 2024 registration, following an earlier move from August 2025 to June 2026 in July 2024. The stated H2-2026 readout window still contains the current November 1, 2026 completion date, so the timing shift does not put the guided window at risk. Enrollment has held flat at its original target of 45 participants, a pattern the operational model classifies as typical for a trial at this stage. NCT06310291VTP-1000 in Adults With Celiac DiseaseNCT06310291
The field
No competitor identified in celiac disease shares VTP-1000's T-cell immunity-induction mechanism; the nearest programs in active development, including Sanofi's OX40L-targeting amlitelimab, Dr. Falk Pharma's transglutaminase-2 inhibitor ZED1227, and Teva's TEV-53408, work through different mechanistic hypotheses. The field includes six active trials across enzyme, peptide, small-molecule, and antibody approaches, none of which uses a vaccine modality aimed at restoring immune tolerance. That isolation means AVALON's result will not be benchmarked against a same-mechanism precedent; the informative outcome is whether higher, repeated dosing preserves the tolerability and antibody signal the company reported from single dosing, without new safety findings that would complicate a move into an efficacy-focused trial.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.